iSpecimen Inc., a healthcare technology company operating an online marketplace for specimen procurement, has released its unaudited interim financial results for the period ending September 30, 2026. The report indicates that the company continues to incur operating losses, as revenue growth has been insufficient to offset increased expenditures in technology and sales and marketing.
Financial data reveals that cash flows from operating activities remain negative. While financing activities resulted in a modest net inflow, this was primarily driven by new equity issuances. In an effort to manage costs, the company’s board has implemented workforce reductions; however, technology spending has increased due to ongoing software development initiatives.
The company’s stock has experienced significant volatility over the past year. As of November 16, 2026, the closing price was $0.596, near the 52-week low of $0.559, compared to a 52-week high of $27.44 reached on November 27, 2025. In response to market conditions, the company has undertaken a 1-for-40 reverse stock split. The company currently maintains a market capitalization of $3,500,000 USD and a price-to-earnings ratio of -0.03.
Management has expressed substantial doubt regarding the company’s ability to continue as a going concern for the upcoming year. This assessment is based on the ongoing challenges in achieving profitability and the critical requirement for additional capital and sustained revenue growth. No material changes to accounting policies were reported during the quarter.




